Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia

Journal of Laboratory and Clinical Medicine

Volumn 141, Issue 4, 2003, Pages 250-256

  Pappu, Anuradha S ^a   Bacon, Sandra P ^a   Illingworth, D Roger ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVALONIC ACID; MEVINOLIN; SIMVASTATIN;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET THERAPY; DRUG WITHDRAWAL; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HETEROZYGOSITY; HUMAN; ISCHEMIC HEART DISEASE; LOW FAT DIET; MALE; RECURRENT DISEASE; TIME SERIES ANALYSIS; URINARY EXCRETION;

EID: 0037388219     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1067/mlc.2003.31     Document Type: Article

References (37)

1. Illingworth DR. Therapeutic use of lovastatin in the treatment of hypercholesterolemia. Drugs of Today 1993;2:201-16.
2. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG CoA reductase inhibitors. Clin Ther 1997;16:366-85.
3. Vega GL, Krauss RM, Grundy SM. Pravastatin therapy in primary moderate hypercholesterolemia: changes in metabolism of apo-B containing lipoproteins. J Intern Med 1990;227:81-94.
4. Bilheimer DW, Grundy SM, Brown MS, Goldstein JL. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoproteins from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci U S A 1983;80:4124-8.
5. Arad Y, Ramakrishnan R, Ginsberg HN. Lovastatin therapy reduces low density lipoprotein apo B levels in subjects with combined hyperlipidemia by reducing the production of apo B containing lipoproteins: implications for the pathophysiology of apo B production. J Lipid Res 1990;31:567-82.
6. Hardeman EC, Endo A, Simoni RD. Effects of compactin on the levels of 3-hydroxy-3 methylglutaryl coenzyme A reductase in compactin resistant C100 and wild-type cells. Arch Biochem Biophys 1984;22:549-61.
7. Shalnick DG, Brown DA, Brown PC, Friedman RL, Hardeman EC, Schimke RT, et al. Mechanism of 3-hydroxy-3 methylglutaryl coenzyme A reductase over-accumulation in the compactin-resistant cell lines. J Biol Chem 1985;260:1991-4.
8. Sinensky M, Logel J. Inhibition of degradation of 3-hydroxy-3 methylglutaryl coenzyme A reductase by mevinolin. J Biol Chem 1983;258:8547-9.
9. Tanaka RD, Edwards PA, Lan S-F, Knoppel EM, Fogelman AM. The effects of cholestyramine and mevinolin on the diurnal cycle of rat hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase. J Lipid Res 1982;23;1026-31.
10. Gebhard RL, Prigge WF, Andreini JP, Freeman ML. Effects of probucol on blood cholesterol and basal and lovastatin-induced 3-hydroxy-3-methylgutaryl coenzyme A reductase activity in mice. J Lab Clin Med 1991;117:299-304.
11. Kroon PA, Hand KM, Huff JW, Alberts AW. The effect of mevinolin on serum cholesterol levels of rabbit with endogenous hypercholesterolemia. Atherosclerosis 1982;44:41-8.
12. Brown MS, Goldstein JL. A receptor mediated pathway for cholesterol homeostasis. Science 1986;232:34-7.
13. Grundy SM. Multifactorial etiology of hypercholesterolemia: implications for prevention of coronary heart disease. Arterioscler Thromb 1991;11:1619-35.
14. Grundy SM, Ahrens Jr EH. Measurements of cholesterol turnover, synthesis and absorption in man, carried out by isotopic kinetic and sterol balance methods. J Lipid Res 1969;10:91-107.
15. Jones PJH, Schoeller DA. Evidence for diurnal periodicity in human cholesterol biosynthesis. J Lipid Res 1990;31:667-73.
16. Kempen HJM, Glatz JFC, Leuven JAG, Vander Voort HA, Katan MB. Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. J Lipid Res 1988;29:1149-55.
17. Parker TS, McNamara DJ, Brown CD, Kolb R, Ahrens Jr EH, Alberts AW, et al. Plasma mevalonate as a measure of cholesterol biosynthesis in man. J Clin Invest 1984;74:795-804.
18. Jones PJH, Pappu AS, Hatcher L, Li ZC, Illingworth DR, Connor WE. Dietary cholesterol feeding suppresses human cholesterol synthesis measured by deuterium incorporation and urinary mevalonic acid levels. Arterioscler Thromb Vasc Biol 1996;16:1222-8.
19. Illingworth DR, Pappu AS, Gregg RE. Increased urinary mevalonic acid excretion in patients with abetalipoproteinemia and homozygous hypobetalipoproteinemia. Atherosclerosis 1989;76:21-7.
20. Lindenthal B, Simatupang A, Dotti MT, Fedrico A, Lutjohann D, von Bergmann K. Urinary excretion of mevalonic acid as an indicator of cholesterol synthesis. J Lipid Res 1996;37:2193-201.
21. Illingworth DR, Bacon S, Pappu AS, Sexton GJ. Comparative hypolipidemic effects of lovastatin and simvastatin in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 1992;96:53-64.
22. Lipid Research Clinic Manual 1. National Heart, Lung and Blood Institute. DHEW publication no. 75-628. Bethesda, Md: National Institutes of Health, 1974:74.
23. Popjak G, Boehm G, Parker TS, Edwards P, Fogelman AM. Determination of mevalonate in blood plasma in man and rat: mevalonate tolerance tests in man. J Lipid Res 1979;20:716-28.
24. Pappu AS, Illingworth DR, Bacon S. Reduction in plasma low-density lipoproteins and urinary mevalonic acid by lovastatin in patients with heterozygous familial hypercholesterolemia. Metabolism 1989;38:542-9.
25. Pappu AS, Illingworth DR. Contrasting effects of lovastatin and cholestyramine on low-density lipoprotein cholesterol and 24-hour urinary mevalonate excretion in patients with heterozygous familial hypercholesterolemia. J Lab Clin Med 1989;114:554-62.
26. SPSS Inc. SPSS statistical software, version 10. Chicago, Ill.
27. Grundy SM, Vega GL. Influence of mevinolin on low density lipoproteins in primary moderate hypercholesterolemia. J Lipid Res 1985;26:1464-75.
28. Ginsberg HN, Le NA, Short MP, Ramakrishnan R, Desnick RJ. Suppression of apolipoprotein production during treatment of cholesteryl ester storage disease with lovastatin: implications for apolipoprotein B synthesis. J Clin Invest 1987;80:1692-7.
29. Arad Y, Ramakrishnan R, Ginsberg HN. Effects of lovastatin therapy on low-density lipoprotein triglycerides metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. Metabolism 1992;41:487-93.
30. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991;151:43-9.
31. Grundy SM, Bilheimer DW. Inhibition of 3-hydroxy-3-methylglutaryl CoA reductase by mevinolin in familial hypercholesterolemia heterozygotes: effects on cholesterol balance. Proc Natl Acad Sci U S A 1984;81:2538-42.
32. Goldberg IJ, Holleran S, Ramakrishnan R, Adams M, Palmer RH, Dell RB, et al. Lack of lovastatin therapy on the parameters of whole body cholesterol metabolism. J Clin Invest 1990;86:801-8.
33. Raal FJ, Pappu AS, Illingworth DR, Pilcher GJ, Marais AD, Firth JC, et al. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolemia. Atherosclerosis 2000;150:421-8.
34. Chin D, Lusky KL, Anderson RGW, Faust R, Goldstein JL, Brown MS. Appearance of crystalloid endoplasmic reticulum in compactin resistant Chinese hamster cells with 500-fold 3-hydroxy-3-methylglutaryl coenzyme A reductase. Proc Natl Acad Sci U S A 1982;79:1185-9.
35. Singer I, Scott IS, Kazazis DM, Huff JW. Lovastatin, an inhibitor of cholesterol synthesis, induces hydroxy methylglutaryl-coenzyme A reductase directly on membranes of expanded smooth endoplasmic reticulum in rat hepatocytes. Proc Natl Acad Sci U S A 1988;85:5264-8.
36. Goldstein JL, Brown MS. Regulation of mevalonate pathway. Nature 1990;343:425-30.
37. Meigs TE, Roseman DS, Simoni RD. Regulation of 3-hydroxy - 3-methylglutaryl-coenzyme A reductase degradation by non-sterol mevalonate metabolite farnesol in vivo. J Biol Chem 1996;271:7916-22.